Company Quick10K Filing
Clovis Oncology
10-Q 2021-03-31 Filed 2021-05-05
10-K 2020-12-31 Filed 2021-02-25
10-Q 2020-09-30 Filed 2020-11-05
10-Q 2020-06-30 Filed 2020-08-07
10-Q 2020-03-31 Filed 2020-05-06
10-K 2019-12-31 Filed 2020-02-26
10-Q 2019-09-30 Filed 2019-11-07
10-Q 2019-06-30 Filed 2019-08-02
10-Q 2019-03-31 Filed 2019-05-07
10-K 2018-12-31 Filed 2019-02-28
10-Q 2018-09-30 Filed 2018-11-01
10-Q 2018-06-30 Filed 2018-08-02
10-Q 2018-03-31 Filed 2018-05-09
10-K 2017-12-31 Filed 2018-02-27
10-Q 2017-09-30 Filed 2017-11-02
10-Q 2017-06-30 Filed 2017-08-03
10-Q 2017-03-31 Filed 2017-05-04
10-K 2016-12-31 Filed 2017-02-23
10-Q 2016-09-30 Filed 2016-11-04
10-Q 2016-06-30 Filed 2016-08-09
10-Q 2016-03-31 Filed 2016-05-09
10-K 2015-12-31 Filed 2016-02-29
10-Q 2015-09-30 Filed 2015-11-06
10-Q 2015-06-30 Filed 2015-08-07
10-Q 2015-03-31 Filed 2015-05-08
10-K 2014-12-31 Filed 2015-02-27
10-Q 2014-09-30 Filed 2014-11-07
10-Q 2014-06-30 Filed 2014-08-08
10-Q 2014-03-31 Filed 2014-05-09
10-K 2013-12-31 Filed 2014-02-28
10-Q 2013-09-30 Filed 2013-11-07
10-Q 2013-06-30 Filed 2013-08-07
10-K 2012-12-31 Filed 2013-03-14
10-Q 2012-09-30 Filed 2012-11-14
10-Q 2012-06-30 Filed 2012-08-10
10-Q 2012-03-31 Filed 2012-05-11
10-K 2011-12-31 Filed 2012-03-15
8-K 2020-11-27
8-K 2020-11-17
8-K 2020-11-05
8-K 2020-11-04
8-K 2020-08-06
8-K 2020-06-04
8-K 2020-05-18
8-K 2020-05-05
8-K 2020-04-14
8-K 2020-04-14
8-K 2020-02-24
8-K 2020-01-07
8-K 2020-01-07
8-K 2019-11-07
8-K 2019-08-22
8-K 2019-08-07
8-K 2019-08-01
8-K 2019-07-01
8-K 2019-06-14
8-K 2019-06-05
8-K 2019-05-07
8-K 2019-05-01
8-K 2019-04-12
8-K 2019-03-14
8-K 2019-02-26
8-K 2019-01-07
8-K 2018-10-30
8-K 2018-10-29
8-K 2018-10-11
8-K 2018-08-01
8-K 2018-06-07
8-K 2018-05-08
8-K 2018-04-16
8-K 2018-04-09
8-K 2018-02-26

Clovis Oncology Financials

CLVS Metrics, Comps, Filings

Quarterly | Annual

Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Equity

Income Statement ($BB Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($BB Quarterly)

Ops, Inv, Fin

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
024 Pharma (EEIG)
11 Good Energy (ELVN)
Supernova Partners Acquisition Co III, Ltd. (STRE-WT)
1347 Capital Corp (TFSC)
Ameri Metro, Inc. (formerly Yellowwood) (ARMT)
Gores Technology Partners, Inc. (GTPAW)
Bioquest Corp (BQST)
BriaCell Therapeutics Corp. (BCTXW)
Ameren Illinois Co (AILNP)
DD3 Acquisition Corp. II (DDMXW)
8i Acquisition 2 Corp. (LAX)
Acumen Pharmaceuticals, Inc. (ABOS)
Aerovate Therapeutics, Inc. (AVTE)
Frontier Investment Corp (FICV)
Gobi Acquisition Corp. (GOBI)
1PM Industries (OPMZ)
1st Century Bancshares (FCTY)
HEALTH REVENUE ASSURANCE HOLDINGS, INC. (HRAA)
Ocean Biomedical, Inc. (OCEA)
ALABAMA POWER CO (APRCP)

Balance Sheet ($MM)2012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash121177162144130372357323304273517483292236355279220228244216276492611464374468291222123109201
Accounts Receivable021613121413161517
Inventory7652869634427252725
PP&E222211121134333755574448461132161615
Assets124180165146131375360650629599832786705663892713645468399365537850805735679968891864785686717
Accounts Payable21224214332376911141511112413141513163129431932
Long-Term Debt288288288288288280280281281588
Liabilities10101212121215152157157443455452463477413412355342368362506506368373655658717710716804
Stockholders' Equity11417015313312036334649847344238833225320041430123311357-417434429936830631223414675-30-87
Income Statement ($MM)2012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue000000000722171719242330333338
Cost of Revenue445
Gross Profit151918
R&D13131518121616232437355057607676756854543233393844536471627178
SG&A233333465556778810109122953353939454249484842
Tax0-0000200-000-1-29-4-29-01-0-1-1-1-0001-0-0-0
Net Income-19-16-18-21-16-19-20-29-31-35-40-55-63-72-99-120-83-129-66-71-58-168-61-52-78-101-90-99-86-120-94
Cash Flow ($MM)2012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-19-14-14-19-14-16-24-20-29-34-34-48-57-72-76-84-68-60-55-80-46-66-101-110-72-98-98-57
Cash Investing1-0-0-0-0-0-10-0-2-0-0-143-0-109-224757525-87163-8410-182-106-17553
Cash Financing-070000-00012780123001111322722138711897